Výsledky vyhledávání - "Arie E. van der Bijl"

Onset of rheumatoid arthritis after COVID-19: coincidence or connected?

Autor: Tom W J Huizinga, Anna H. Roukens, Femke B G Lamers-Karnebeek, Veerle F. A. M. Derksen, Theresa Kissel, Arie E. van der Bijl, René E. M. Toes, Diane van der Woude, Annemarie C Venhuizen

COVID-19, caused by SARS-CoV-2, can lead to severe inflammation and has been suggested to induce autoimmune phenomena. Multiple studies have reported autoantibodies in patients with COVID-19, particularly anti-cardiolipin, anti-β2-glycoprotein I and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01ff88dbade276335ab284dbdafe1c08
https://doi.org/10.1136/annrheumdis-2021-219859

Zobrazit plný text záznamu

The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion

Autor: Henriette Baan, Marloes Vermeer, M.D. Posthumus, Mart A F J van de Laar, H.L.M. Brus, Piet L. C. M. van Riel, Arie E. van der Bijl, Hillechiena H. Kuper

Publikováno v: Rheumatology, 51, 6, pp. 1076-80
Rheumatology, 51, 1076-1080. Oxford University Press
Rheumatology, 51(6), 1076-1080. Oxford University Press
Rheumatology, 51, 1076-80

Contains fulltext : 109910.pdf (Publisher’s version ) (Closed access) OBJECTIVES: The provisional ACR/European League Against Rheumatism (EULAR) definition of remission in RA requires a score of 1 despite fulfilment of the remaining criteria (TJC28

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ecb03d826ad29c4206c6ad852343e4
https://hdl.handle.net/2066/109910

Zobrazit plný text záznamu

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

Autor: Gerd R Burmester, Arie E. van der Bijl, C Antoni, Hartmut Kupper, Joachim R. Kalden, Kristina Unnebrink, Sonja Kary, Christina Beckmann, Ferdinand C. Breedveld

Publikováno v: Clinical Rheumatology

This prospective open-label pilot study evaluated the effectiveness and safety of adalimumab and the relationship to antibodies against infliximab (IFX) in adult patients with active rheumatoid arthritis (RA) who had been treated previously with IFX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d77a0e77d7b583d1f1393a1b102a6f6d
https://pubmed.ncbi.nlm.nih.gov/18350329

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání